Ya lo veo.....a ver si van a sacar alguna PR en afters o mañana en pre que la catapulte... A lo mejor pillo unas pocas otra vez antes del cierre... Yo esperaba que cayera más ante la falta de news en la conferencia.... Pero está el tema del vencimiento del viernes...
IVI, INOVIO, and KNIH to Partner with CEPI in Phase 1/2 Clinical Trial of INOVIO's COVID-19 DNA Vaccine in South Korea
April 16, 2020
- The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6.9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO's COVID-19 vaccine candidate based on their well-established DNA platform technology
INOVIO's DNA vaccine platform is also utilized in their MERS vaccine, INO-4700, for which IVI previously conducted Phase I clinical testing with GeneOne Life Science in South Korea..
This news follows the announcement from the Korean Ministry of Food and Drug Safety made on April 13th that they will adopt a fast-track approval process for COVID-19 vaccine and treatment clinical trials. The period of clinical trial screening will be shortened to seven days (down from 30 days
Additionally, vaccines developed with a proven safety platform, such as INOVIO's DNA platform, will be exempt from toxicology tests which will minimize data submission and expedite clinical trials.
Dynavax and Sinovac Announce Collaboration to Develop a Coronavirus (COVID-19) Vaccine
Apr 16, 2020 at 7:30 AM EDT
The collaboration will combine Dynavax’s CpG 1018, the adjuvant contained in U.S. FDA-approved HEPLISAV-B vaccine, with Sinovac’s chemically inactivated coronavirus vaccine candidat
